Formulary guidance and transparency from P&T to point of care


Reality Check on Hepatocelluar Carcinoma

Market access for hepatocelluar carcinoma treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, almost 55% of the lives under commercial formularies are covered with utilization management restrictions
  • Class Trends: In May 2019, the FDA expanded the label of Cyramza (ramucirumab) to include the treatment of hepatocellular carcinoma in people with an alpha fetoprotein (AFP) of >400 ng/mL who previously were treated with Nexavar (sorafenib)  
  • Key Findings: Most payers have written policies for these products for both approved and off-label indications. Policies are generally written to label or to NCCN guidelines   

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.